Trial
NCT04478695
Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Amgen
Collaborators
Merck Sharp & Dohme LLC
Condition
Relapsed or Refractory Acute Myeloid Leukemia
Intervention
AMG 330
Why stopped
Amgen Decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-03-08